-5%
Febuxit is indicated for the long-term management of hyperuricemia in adults with gout. It is not recommended for individuals with asymptomatic hyperuricemia.
Febuxostat, the active ingredient in Febuxit, is a non-purine selective xanthine oxidase (XO) inhibitor. By inhibiting XO, the enzyme responsible for converting hypoxanthine to xanthine and then to uric acid, it effectively lowers serum uric acid levels.
Importantly, Febuxostat does not interfere with other enzymes involved in purine or pyrimidine metabolism at therapeutic doses.